Yazar "Beyaz, C." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly
    (Springer Heidelberg, 2017) Tuzcu, S.; Durmaz, S. A.; Carlioglu, A.; Demircan, Z.; Tuzcu, A.; Beyaz, C.; Tay, A.
    Objective. Growth hormone (GH) and insulinlike growth factor-1 (IGF-1) play a major role in bone homeostasis. In this study, we aimed to assess bone mineral density (BMD) in active acromegaly. Materials andmethods. A total of 29 patients with active acromegaly (age 46.10 +/- 13.27 years; body mass index [BMI]: 29.51 +/- 4.91 kg/m(2)) and 42 healthy individuals matched for age and BMI (age: 40.35 +/- 11.74 years; BMI: 28.18 +/- 7.35 kg/m(2)) were included in the study. BMD wasmeasured by DXA. Results. The mean levels of GH and IGF1 were found to be 12.61 +/- 11.34 ng/ml and 676.47 +/- 316.19 ng/ml in acromegaly, respectively, while the mean levels of GH and IGF-1 were found to be 0.59 +/- 0.81 ng/ml (p = 0.0001) and 178.17 +/- 57.11 ng/ml (p = 0.0001) in the control group, respectively. Only total hip t-score was determined to be significantly lower in acromegaly compared to the control group (p = 0.037). No significant differences were found between the other parameters in DXA and only a positive correlation was found between IGF-1 levels and L1-L4 BMD (r = 0.259, p = 0.029). Conclusions. Although GH and IGF-1 levels were increased in acromegalic patients, no significant difference was found in terms of vertebral BMD. Only hip t-scores were found to be lower in acromegalic patients, but this low hip t-score did not reach the osteopenic level. The positive correlation between IGF-1 and lumbar vertebral BMD suggested a more prominent effect of IGF-1 on BMD compared to GH.
  • [ X ]
    Öğe
    Results of imatinib mesylate therapy in chronic myeloid leukemia: Experience of a single center
    (Ferrata Storti Foundation, 2007) Pasa, S.; Boyraz, T.; Beyaz, C.; Sayar, S.; Atayan, Y.
    [Abstract Not Available]